Chiesi’s Juxtapid Wins NMPA Approval for Rare Cholesterol Disorder in China
Chiesi Group’s China unit announced that the National Medical Products Administration (NMPA) has granted marketing...
Chiesi Farmaceutici
Chiesi Fabry Drug Pegunigalsidase Alfa Wins CHMP Backing for Extended Dosing
Chiesi Group announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended...
Chiesi’s Raxone Begins LHON Treatment in China, First World‑Approved Therapy
Chiesi Group announced that the first patients have initiated treatment with Raxone (idebenone 150 mg) at...
Chiesi Group Launches First EB Wound Treatment in China
The Italian Chiesi Group announced on October 25, 2025, the successful launch of its innovative...
Jemincare Group Announces NMPA Approval of Generic Clenil for Asthma Treatment
China-based Jiangxi Jemincare Group has announced that it has received marketing approval from the National...
Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical’s HSK31858 for Respiratory Diseases
Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co.,...
Chiesi Farmaceutici and Shanghai Pharmaceutical Partner on Distribution at CIIE
Among the series of deals secured by multinational corporations at the 6th China International Import...